IL17A and psoriasis: Given the highly unmet needs in patients with psoriasis involving difficult-to-treat areas and the promising profile of bimekizumab as a dual IL-17A/IL-17F inhibitor, our study aims to assess the real-world effectiveness and safety of this drug in this specific subpopulation.